FY2016 EPS Estimates for Alnylam Pharmaceuticals Inc. Lifted by Analyst (ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) – Equities researchers at FBR & Co increased their FY2016 EPS estimates for shares of Alnylam Pharmaceuticals in a research report issued on Thursday. FBR & Co analyst C. James now expects that the brokerage will post earnings of ($3.82) per share for the year, up from their previous forecast of ($4.11). FBR & Co currently has a “Outperform” rating and a $100.00 target price on the stock. FBR & Co also issued estimates for Alnylam Pharmaceuticals’ Q4 2016 earnings at ($0.48) EPS, FY2017 earnings at ($3.13) EPS, FY2018 earnings at ($2.73) EPS, FY2019 earnings at ($0.34) EPS and FY2020 earnings at $4.45 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The business’s revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) earnings per share.
Other research analysts also recently issued reports about the company. Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Morgan Stanley downgraded Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $38.00 to $36.00 in a research note on Friday. Finally, Jefferies Group reduced their price objective on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating for the company in a research note on Thursday. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Monday. The stock’s market capitalization is $2.94 billion. The stock’s 50 day moving average is $70.69 and its 200-day moving average is $66.05. Alnylam Pharmaceuticals has a 52 week low of $33.16 and a 52 week high of $110.75.
Hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. increased its stake in shares of Alnylam Pharmaceuticals by 2,138.1% in the second quarter. Macquarie Group Ltd. now owns 20,143 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 19,243 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Alnylam Pharmaceuticals by 63.0% in the second quarter. Royal Bank of Canada now owns 51,314 shares of the biopharmaceutical company’s stock worth $2,847,000 after buying an additional 19,827 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Alnylam Pharmaceuticals by 3.6% in the second quarter. Public Employees Retirement System of Ohio now owns 28,961 shares of the biopharmaceutical company’s stock worth $1,607,000 after buying an additional 1,000 shares during the period. Calvert Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 36 shares during the period. Finally, Amalgamated Bank purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $859,000. 85.96% of the stock is owned by hedge funds and other institutional investors.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.00% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.